UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000053865 |
|---|---|
| Receipt number | R000061475 |
| Scientific Title | Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting |
| Date of disclosure of the study information | 2024/03/14 |
| Last modified on | 2024/03/14 17:59:00 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting
Acronym
Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting
Scientific Title
Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting
Scientific Title:Acronym
Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting
Region
| Japan |
Condition
Condition
Patients receiving highly or moderately emetogenic chemotherapy
Classification by specialty
| Gastroenterology | Hepato-biliary-pancreatic medicine | Pneumology |
| Hematology and clinical oncology | Gastrointestinal surgery | Hepato-biliary-pancreatic surgery |
| Breast surgery | Obstetrics and Gynecology | Urology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To investigate the efficacy and safety of fosnetupitant in patients receiving highly or moderately emetogenic chemotherapy
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
1)Common Terminology Criteria for Adverse Events (CTCAE) v5.0
2)MASCC Antinausea and vomiting Tool (MAT)
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1)Adult
2)Patients receiving highly or moderately emetogenic chemotherapy
Key exclusion criteria
patients with severe dementia
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | Kosuke |
| Middle name | |
| Last name | Nishizawa |
Organization
Toho University Sakura Medical Center
Division name
Department of Pharmacy
Zip code
285-8741
Address
564-1, Shimoshizu, Sakura City, Chiba
TEL
043-462-8811
k-nishizawa@med.toho-u.ac.jp
Public contact
Name of contact person
| 1st name | Kosuke |
| Middle name | |
| Last name | Nishizawa |
Organization
Toho University Sakura Medical Center
Division name
Department of Pharmacy
Zip code
285-8741
Address
564-1, Shimoshizu, Sakura City, Chiba
TEL
043-462-8811
Homepage URL
k-nishizawa@med.toho-u.ac.jp
Sponsor or person
Institute
Toho University Sakura Medical Center
Institute
Department
Personal name
Funding Source
Organization
Self funding
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Ethics Committee of Toho University, Sakura Medical Center
Address
564-1, Shimoshizu, Sakura City, Chiba
Tel
043-462-8811
sakura.rinri@ext.toho-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2024 | Year | 03 | Month | 14 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2023 | Year | 12 | Month | 15 | Day |
Date of IRB
| 2023 | Year | 12 | Month | 15 | Day |
Anticipated trial start date
| 2024 | Year | 03 | Month | 14 | Day |
Last follow-up date
| 2026 | Year | 10 | Month | 25 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
retrospective study
Management information
Registered date
| 2024 | Year | 03 | Month | 14 | Day |
Last modified on
| 2024 | Year | 03 | Month | 14 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061475
